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Abstract 
Objectives: Bloodstream infection results in significant short-term morbidity and mortality. No literature review has 
studied the long-term outcome following a bloodstream infection. This PROSPERO registered systematic review 
evaluated studies, which measured the association of a bloodstream infection with long-term morbidity and mortality. 
Methods: Databases were systematically searched for studies of adult patients reporting morbidity and/or mortality one 
year or more following a bloodstream infection in comparison to a matched cohort without a bloodstream infection. 
Results: Ten observational studies were included in the final analysis. Five studies assessed only mortality, two assessed 
morbidity and mortality and three studies assessed morbidity only. The one year mortality ranged from between 8 and 
48% for patients with bloodstream infection. The pooled risk ratio of death at one year was significantly higher for 
patients with bloodstream infection when compared to the matched cohort (RR 4.04 [95% CI 1.84-8.87]). 
Conclusions: Bloodstream infection was associated with poor long-term outcome measured at one year when compared 
to matched controls.  More evidence is needed to determine if this association is causative.  
Keywords: bacteraemia, septicaemia, bloodstream infection, long term, outcome, endpoint, mortality. 
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Introduction 
Bloodstream infections (BSI) are a significant cause of morbidity and mortality worldwide (1). The practice of measuring 
mortality at one month following a BSI is well established (2,3). A recent review of clinical trials of antibiotics for patients 
with bloodstream infection in the last 10 years demonstrated all outcomes were measured at 90 days or less (4).  
BSI have been associated with high long-term mortality, subsequent cardiovascular disease (5–7) and increased risk of 
recurrent bloodstream infection (8). The interpretation of the impact of BSI in many of these studies is limited by the 
absence of a suitable comparator group (5–7). The measurement of outcome following a serious infection beyond the 
short term is potentially confounded by co-morbid disease as BSI often occurs in patients with pre-disposing disorders, 
which carry a high risk of increased morbidity and premature death when compared to the general population. Risk 
factors that have been associated with acquisition of a bloodstream infection include: diabetes, HIV infection, chronic 
liver disease, previous and repeated hospitalisation, corticosteroid therapy use, chronic renal failure, presence of a solid 
tumour and overall degree of co-morbid disease (9). 
The long-term sequelae from other serious infections have been well described (10). Sepsis has been evaluated in 
multiple studies using outcome measurements such as: quality of life adjusted years, subsequent cardiovascular risk and 
mortality beyond one year (11). Patients with sepsis have ongoing mortality beyond the usual short-term outcome time 
point with survivors consistently demonstrating impaired quality of life (11).  
Understanding the long-term impact of a BSI on mortality and morbidity is important to adequately establish disease 
burden, define when to measure endpoints for clinical trials and to guide allocation of healthcare and research 
resources. 
The objectives of this systematic review were to i) identify studies that assessed the outcome (either morbidity or 
mortality) following a bloodstream infection at one year or greater ii) where morbidity was assessed, describe the 
methods used to assess and describe associated morbidities, iii) include studies which included a matched cohort of 
patients without bloodstream infection as a comparator. 
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Methods 
This study has been reported in accordance with the PRISMA guidelines on reporting systematic reviews (12) and was 
registered with the PROSPERO international prospective register of systematic reviews (PROSPERO 
2016:CRD42016052052) on 8th December 2016, 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016052052.  
We searched the following electronic bibliographic databases: EMBASE, PubMed, The Cochrane Library, Scopus and 
references from included articles. The search strategy included terms relating to bloodstream infection and describing 
an outcome in terms of morbidity or mortality. The search protocol was developed in consultation with a specialist 
medical librarian. The terms used were (bloodstream infection OR bacteraemia OR septicaemia) AND (cohort OR follow 
up OR longitudinal OR prospective OR retrospective studies) NOT (paediatric OR child OR neonate OR perinatal OR baby 
OR toddler). Studies reviewed were restricted to English and studies exclusively of paediatric patients were excluded.  
Reviews, case reports and small case series were excluded (<10 total number of patients). Studies were excluded if there 
was no case match or case control with a patient without bloodstream infection. Studies assessing patients with sepsis 
without a large proportion of bloodstream infections (>80%) were also excluded. There were no exclusions based on the 
date of the study. The searches were re-run prior to the final analyses. 
The PECO criteria used to select studies were as follows: 
 Patient population/problem: adult patients 
 Exposure:   bloodstream infection 
 Comparator:   adult patients without bloodstream infection 
 Outcome:   morbidity or mortality at or beyond 1 year 
Data Extraction and management 
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The authors JFM and ER independently screened search results according to the PECO criteria. Details of each study 
were extracted and results tabulated. Patient demographics, organisms cultured, nature of matching and ratio, and 
outcome measurements were extracted from the original publications.  
Outcome measures and definitions 
The time to follow up must have occurred at one year or beyond. Reasonable measures to exclude common 
bloodstream contaminants were assessed. Mortality was the primary endpoint. Morbidity measures were included if 
validated criteria were used as a definition of condition or event. 
Data analysis 
Analyses were performed in the statistical program R (13) with the Metafor statistical software package (14),  and 
Graphpad prism version 7 (15). Studies comparing mortality and exposure to bloodstream infection were included in the 
pooled analysis. Unadjusted mortality was compared between the two cohorts (BSI and non-BSI) at one year. Due to 
variation in organism and host across the different studies heterogeneity was expected and results were combined with 
a random effects model (16) . Heterogeneity between studies was evaluated using the Q statistic (p <0.01 significant 
heterogeneity) and I2 tests (>56% likely high heterogeneity) (17). Cumulative difference in unadjusted mortality and 
associated risk ratios between the BSI and non BSI cohorts at each reported time interval up to one year were plotted as 
an assessment of the rate of change over time in mortality between the two cohorts. Unadjusted relative risk of death 
and 95% confidence interval was calculated for each time point based on published rates of mortality in each study. 
Results 
Study Characteristics 
The search strategy identified 10,135 citations using the described search strategy as shown in figure 1. Two hundred 
and forty-one abstracts and 39 full-text publications were chosen for full review. Ten studies met our inclusion criteria. 
Six studies were multicentre studies and four were single centre studies. Study characteristics as shown in table 2. There 
were no international multicentre matched studies of long term outcome following a bloodstream infection. JFM and 
HW completed assessment of the selected studies utilising the Newcastle-Ottawa Quality Assessment Scale to 
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determine the quality of the study relative to our question of interest as described in table 1. There were no randomised 
clinical trials for BSI that used outcome measures at one year or beyond.  
Mortality 
Long term follow-up for mortality was reported in seven of the ten studies with the duration of follow-up ranging from 1 
to 12 years (18–24). Mortality was measured at variable intervals within the follow-up period with one month the most 
commonly reported mortality time point other than one year (19–21,24).  
The seven studies which assessed mortality evaluated this outcome in comparison to matched controls, which were 
non-BSI hospital controls in four studies and population controls in the other three. All studies with the exception of one 
(25)  included adjustments for co-morbid disease with this most commonly measured as a Charlson index or score(26). 
Variation in mortality was seen in the matched group dependent upon the case selection method. Mortality in the three 
studies using non-BSI patients as controls was (BSI vs non-BSI) 48% vs. 27% (23), 60% vs. 6% (22)and 29.7 vs. 23.9% (24). 
Studies reporting mortality in comparison to population controls (BSI vs population control) describe mortality of 44.6% 
vs 4.1% (18), 41.4% vs 2.6% (27)and 8% vs 3.9%(28). Pooled random effects model of mortality at one year is shown in 
figure 2. The pooled risk ratio of death for patients with BSI of was 4.04 (95% Confidence interval 1.84 – 8.87) when 
compared to the non-BSI cohort. There was a high degree of heterogeneity amongst the included studies as shown in 
the funnel plot in appendix 1 (Q statistic p = <0.001 and I2 99.88%).  
The plot of cumulative difference in mortality demonstrated a divergent mortality over time between the BSI and 
non-BSI cohorts as shown in figure 3. Table 3 describes a significant increase in relative risk of death in patients with BSI 
in all but one study.  
Studies that utilised hospitalised patients as the matched cohort had an odds ratio of mortality of 1.99 (95% CI 1.87, 
2.11), in contrast studies using a general population matched cohort had a statistically significant (p <0.0001) odds ratio 
of 18.92 (95% CI 18.40, 19.47).  
Cause of death 
Reference to the cause of death was made in three of the seven studies reporting mortality (18,23,25,27).   
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Leibovici and colleagues (23) reported on bacterial infection as a cause of death within the first and second month post 
bloodstream infection. Attributed cause of death due to infection in the BSI group declined over the first two months of 
follow-up (21 and 12% respectively). In the matched group the reported rate of death from infection over the same 
period was 2 and 7% respectively. Cause of death in the longer term was not assessed in this study.  
Nielsen and colleagues (27) reported within the first year, cancer and cardiovascular disease were the most common 
causes of death in patients with bloodstream infection. The most common causes of death were cancer and 
cardiovascular disease (54%) in patients with BSI who survived beyond one year. Gotland and colleagues study of 
S.aureus showed cancer as the overall leading cause of death accounting for 1 in 4 deaths (18). 
Morbidity 
Standardised morbidity measures were reported in five of the studies identified (20,24,29–31)(Table 4). Risk of 
functional decline and quality of life was significant amongst BSI patients at 3 months post index event as measured with 
the Barthel-20 (aRR 5.1 95% CI 1.2-22.3) and EQ-5D-3L (aRR 1.3 95% CI 0.8-2.1) respectively(29). These differences were 
less at 1 year for functional status (aRR 1.6 CI 0.5-4.5) and remained the same for quality of life (aRR 1.3 CI 0.8-1.2) (32). 
This study included 71 patients with first time community acquired bloodstream infection and compared them to 71 
hospitalised, blood culture negative patients.  
Higher rates of sick leave utilisation were identified in patients with bloodstream infection (aRR 1.51; CI 1.34 to1.70) 
(20). Rates of venous thromboembolism were increased amongst a population study of patients with Staphylococcus 
aureus bloodstream infection (31). This increase in incidence was seen in a population study of community acquired 
bloodstream infection with a collection of different pathogens at 90 days but did not remain significant at one year (24). 
There was no significant differences in the rates of myocardial infarction or stroke amongst bloodstream infection 
patients when compared to culture-negative controls (21). 
Discussion 
This systematic review identified ten studies that measured long-term mortality or morbidity as an outcome following a 
bloodstream infection in comparison to a non-BSI cohort. These were all observational studies, which included different 
pathogens and included community, health-care associated and hospital acquired infections. Some heterogeneity was 
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expected as studies of this type define different criteria for the included pathogen, the selection of the matched 
population and the degree and measurement of comorbidity. All studies with the exception of one (25) have attempted 
to account for age, hospitalisation, co-morbid disease states by matching and adjustments in analysis. A significant 
increase in mortality was seen in six of the seven studies when measured at one year.  
The degree of mortality varied considerably ranging from 18 to 60% mortality in the BSI and 2.6 to 27% in the non-BSI 
group at one year across the seven studies reporting mortality. The highest mortalities were seen in a study of liver 
transplant patients (60%), a study of exclusively Staphylococcus aureus BSI (44.6%) and in the oldest study in the group 
(48%) (18,23,33) . A high co-morbidity cohort – liver transplant, virulence of the selected pathogen (S. aureus) and high 
baseline mortality (27% in non-BSI cohort) may account for the higher mortality seen in these studies. Conversely the 
lowest mortality was seen in a study of patients selected for being part of the workforce immediately prior to acquiring 
their BSI which resulted in a lower overall age of the cohort (20 to 58 years) and perhaps lesser degree of co-morbidity 
and frailty which might have contributed to the lower mortality (34) . The nature of the matched population had a large 
impact on the odds ratio of death. There was a large reduction in the odds ratio of death when comparing hospital 
versus population matched studies. The odds ratio of death was significantly different (10 fold less) when population 
matched cohort studies were compared to hospital matched studies (OR 18.92 to OR 1.99 respectively).  Further 
interrogation of potential moderators of the mortality outcome was limited by the small number of studies that have 
attempted to address this question. 
Studies that measured short-term mortality suggest a slowing in the rate of divergence of mortality between BSI and 
non-BSI beyond ninety days as evidenced by a flattening in the gradient seen in figure 2. Whilst the greatest degree of 
mortality likely occurs early (<90 days) mortality continues to diverge in many of the studies beyond this point. The two 
studies that reported the second and third greatest divergence in mortality over the one year period compared BSI to 
non-BSI from population controls rather than hospital controls (35,36) (Figure 2).  
The difficulty in assessing long-term outcome is extricating the impact the bloodstream infection has on mortality from 
the patient type who is at risk of acquiring a bloodstream infection. Patients at risk of bloodstream infection are those 
who experience multiple hospitalisations and have multiple co-morbidities (9). All studies with the exception of one, 
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included adjustment for confounding. However the potential for residual and unmeasured confounding would be seen 
as highly probable. 
Three studies reported cause of death with different methodology limiting their comparability (35–37). One study only 
described infection as the attributable cause, which was higher in the bloodstream infection group but was not 
specifically measured in the longer term (37). Two studies reported cause of mortality in comparison to population 
controls, one study categorised cause of death to attributable organ system and the second by disease state (35,36). The 
differential results, reflects different temporal analysis, variance in patient cohort and/or different causative pathogens 
(first time community acquired bacteraemia versus S. aureus bacteraemia). 
Standardised morbidity outcomes also demonstrated some association with poorer outcome for patients with 
bloodstream infection with some measures. There were two studies, which assessed functional outcomes via different 
measures. A small prospectively matched cohort of 71 patients with bloodstream infection assessed function and quality 
of life via the validated tools Barthel-20 (38) and EQ-5D (39) whilst the other employed the endpoints of sick leave 
utilisation and disability. A differential deterioration in function was apparent at 3 months though less so at 12 months 
when compared to the matched cohort no difference in QOL measures was demonstrated. Increased sick leave 
utilisation also occurred in patients with bloodstream infection.  
The associated incidence of co-morbid disease was assessed by measurement of venous thromboembolism by two 
studies and by myocardial infarction and stroke in one study. Both of the studies examining the occurrence of venous 
thromboembolism demonstrated an association with bloodstream infection though the effect appears to occur within 
the first 90 days post infection with limited association at 1 year. The studies assessed different groups of pathogens (S. 
aureus and community acquired bloodstream infection) and the subsequent occurrence of venous thromboembolism 
though they differed in the matched cohort. Mejer (31) utilised population controls and Dalager-Pedersen (40) used 
hospitalised controls which may account for the differences in findings. The association of venous thromboembolism has 
been previously described in patients with acute infectious diseases and sepsis (41).  
There is a large body of evidence describing the consequences of severe infections extend beyond the first month (10). 
Studies assessing long term outcomes following sepsis have also demonstrated poor outcomes in terms of morbidity and 
mortality. These studies demonstrated increased mortality beyond the traditional outcome measure time points. Quality 
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of life and functional status have also been shown to be poorer in survivors of sepsis (42–45). The poor long-term 
outcome in sepsis was proposed to be due to one of three possible explanations.  1. Sepsis usually happens in the 
elderly and sick, and it causes deterioration in the life expectancy a functional status as an acute non-specific event. 2. 
An interaction exists between specific mechanisms of sepsis and underlying disorders. 3. Long-term consequences 
directly relate to the infection (10). Explanations 2 and 3 may be influenced by the acute management of the disease 
and may subsequently influence the long-term outcome of the individual (10). The observed long-term risk of 
cardiovascular events (46), and vulnerability to subsequent infection have been associated with increased long term 
morbidity and mortality in sepsis cohorts (47). Endovascular inflammation and ongoing risk of infection could result in an 
interaction between acute infective episode, underlying disease state and long-term outcome. 
Whilst there is overlap with sepsis, a bloodstream infection is not necessarily synonymous with sepsis. A prospective 
multi-centre survey of 23 hospitals in France identified only 39.9% of patients with bloodstream infection with severe 
septic or septic shock according to sepsis 2 guideline criteria (48,49).  
In conclusion, this systematic review highlights an association between bloodstream infection and poor long-term 
patient outcomes. The heterogenous nature of the included studies and the small number of studies result in an 
insufficient body of evidence to consider the association a causal interaction. 
Study design for understanding the long-term impact of BSI could be better informed by combining positive design 
elements of the studies assessed in this review.  Large scale studies matched for age and gender with adjustments for 
co-morbidity and collection of date of death to allow high resolution comparative adjusted survival curves would 
provide valuable information as to the most relevant time to measure mortality following a bloodstream infection. 
Assessment of cause of death and associated subsequent disease states such as cardiovascular events and infection 
would be valuable in the formulation of a testable hypothesis of pathophysiological interaction between BSI and 
associated co-morbidity and long-term outcome. Measurement of morbidity would ideally incorporate a standardised 
measurement of functional or performance and quality of life. The application of these tools to large scale population 
studies would be impractical and would be better assessed in small scale studies then correlated to measurements more 
applicable to large scale data capture such as hospital re-admission rate, utilisation of sick leave or timing of return to 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
work. This would provide some validation of surrogate markers of function and quality of life for use in large-scale 
population studies. 
Understanding when to measure survival to reflect the true burden of mortality and how accurately reflect functional 
outcomes would provide useful metrics for measurement of outcomes in clinical trials of severe infections that would be 
highly relevant to patients and clinicians at the bedside.  
Funding Source 
This research did not receive any specific grant from funding agencies in the public, commercial, or 
not-for-profit sectors. 
Conflict of Interest Disclosure 
The authors declare no conflicts of interest 
References 
1.  Goto M, Al-Hasan MN. Overall burden of bloodstream infection and nosocomial bloodstream infection in North 
America and Europe. Clin Microbiol Infect 2013 Jun;19(6):501–9.  
2.  Goto M, Al-Hasan MN. Overall burden of bloodstream infection and nosocomial bloodstream infection in North 
America and Europe. Clin Microbiol Infect. 2013 Jun;19(6):501–9.  
3.  Sogaard M, Norgaard M, Dethlefsen C, Schonheyder HC. Temporal Changes in the Incidence and 30-Day Mortality 
associated with Bacteremia in Hospitalized Patients from 1992 through 2006: A Population-based Cohort Study. 
Clin Infect Dis. 2011 Jan 1;52(1):61–9.  
4.  Harris PNA, McNamara JF, Lye DC, Davis JS, Bernard L, Cheng AC, et al. Proposed primary endpoints for use in 
clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition. Clin 
Microbiol Infect. 017 Aug;23(8):533-541.  
5.  Jafarzadeh SR, Thomas BS, Warren DK, Gill J, Fraser VJ. Longitudinal Study of the Effects of Bacteremia and Sepsis 
on 5-year Risk of Cardiovascular Events. Clin Infect Dis. 2016 Aug 15;63(4):495–500.  
6.  Laupland KB, Zygun DA, Doig CJ, Bagshaw SM, Svenson LW, Fick GH. One-year mortality of bloodstream 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
infection-associated sepsis and septic shock among patients presenting to a regional critical care system. 
Intensive Care Med. 2005 Feb;31(2):213–9.  
7.  Lillie PJ, Allen J, Hall C, Walsh C, Adams K, Thaker H, et al. Long-term mortality following bloodstream infection. 
Clin Microbiol Infect. 2013 Oct;19(10):955–60. Available from:  
8.  Al-Hasan MN, Eckel-Passow JE, Baddour LM. Recurrent gram-negative bloodstream infection: a 10-year 
population-based cohort study. J Infect. 2010 Jul;61(1):28–33.  
9.  Bassetti M, Trecarichi EM, Mesini A, Spanu T, Giacobbe DR, Rossi M, et al. Risk factors and mortality of 
healthcare-associated and community-acquired Staphylococcus aureus bacteraemia. Clin Microbiol Infect. 2012 
Sep;18(9):862–9.  
10.  Leibovici L. Long-term consequences of severe infections. Clin Microbiol Infect. 2013 Jun;19(6):510–2.  
11.  Winters BD, Eberlein M, Leung J, Needham DM, Pronovost PJ, Sevransky JE. Long-term mortality and quality of 
life in sepsis: A systematic review*. Crit Care Med. 2010 May ;38(5):1276–83.  
12.  Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and 
meta-analyses: the PRISMA statement. BMJ. 2009 Jul 21;339:b2535.  
13.  Team RC. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical 
Computing; 2016.  
14.  Wolfgang V. metafor: Meta-Analysis Package for R. Journal of Statistical Software; 2010.  
15.  Software G. Prism for Mac OS X. La Jolla, California USA;  
16.  DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 Sep;7(3):177–88.  
17.  Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002 Jun 15;21(11):1539–58.  
18.  Gotland N, Uhre ML, Mejer N, Skov R, Petersen A, Larsen AR, et al. Long-term mortality and causes of death 
associated with Staphylococcus aureus bacteremia. A matched cohort study. J Infect. 2016 Oct;73(4):346–57.  
19.  Nielsen SL, Lassen AT, Gradel KO, Jensen TG, Kolmos HJ, Hallas J, et al. Bacteremia is associated with excess 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
long-term mortality: a 12-year population-based cohort study. J Infect. 2015 Feb;70(2):111–26.  
20.  Dalager-Pedersen M, Koch K, Thomsen RW, Schønheyder HC, Nielsen H. The effect of community-acquired 
bacteraemia on return to workforce, risk of sick leave, permanent disability pension and death: a Danish 
population-based cohort study. BMJ Open. 2014 Jan 29;4(1):e004208.  
21.  Dalager-Pedersen M, Søgaard M, Schønheyder HC, Nielsen H, Thomsen RW. Risk for myocardial infarction and 
stroke after community-acquired bacteremia: a 20-year population-based cohort study. Circulation. 2014 Apr 
1;129(13):1387–96.  
22.  Karvellas CJ, McPhail M, Pink F, Asthana S, Muiesan P, Heaton N, et al. Bloodstream infection after elective liver 
transplantation is associated with increased mortality in patients with cirrhosis. J Crit Care. 2011 Oct;26(5):468–
74.  
23.  Leibovici L, Samra Z, Konigsberger H, Drucker M, Ashkenazi S, Pitlik SD. Long-term survival following bacteremia 
or fungemia. JAMA. 1995 Sep 13 ;274(10):807–12.  
24.  Dalager-Pedersen M, Søgaard M, Schønheyder HC, Thomsen RW, Baron JA, Nielsen H. Venous thromboembolism 
after community-acquired bacteraemia: a 20-year danish cohort study. Salluh JIF, editor. PLoS One. 2014 Jan 
23;9(1):e86094.  
25.  Tauriainen T, Kinnunen E-M, Laitinen I, Anttila V, Kiviniemi T, Airaksinen JKE, et al. Transfusion and blood stream 
infections after coronary surgery. Interact Cardiovasc Thorac Surg. England; 2017 Sep;  
26.  Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in 
longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.  
27.  Nielsen SL, Lassen AT, Gradel KO, Jensen TG, Kolmos HJ, Hallas J, et al. Bacteremia is associated with excess 
long-term mortality: A 12-year population-based cohort study. J Infect. 2015 Feb;70(2):111–26.  
28.  Dalager-Pedersen M, Koch K, Thomsen RW, Schønheyder HC, Nielsen H. The effect of community-acquired 
bacteraemia on return to workforce, risk of sick leave, permanent disability pension and death: a Danish 
population-based cohort study. BMJ Open. 2014 Jan 29;4(1):e004208.  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
29.  Dalager-Pedersen M, Thomsen RW, Schønheyder HC, Nielsen H. Functional status and quality of life after 
community-acquired bacteraemia: a matched cohort study. Clin Microbiol Infect. 2016 Jan;22(1):78.e1-8.  
30.  Dalager-Pedersen M, Søgaard M, Schønheyder HC, Nielsen H, Thomsen RW. Risk for myocardial infarction and 
stroke after community-acquired bacteremia: a 20-year population-based cohort study. Circulation. 2014 Apr 
1;129(13):1387–96.  
31.  Mejer N, Westh H, Schønheyder HC, Jensen AG, Larsen AR, Skov R, et al. Increased risk of venous 
thromboembolism within the first year after Staphylococcus aureus bacteraemia: a nationwide observational 
matched cohort study. J Intern Med. 2014 Apr;275(4):387–97.  
32.  Dalager-Pedersen M, Thomsen RW, Schønheyder HC, Nielsen H. Functional status and quality of life after 
community-acquired bacteraemia: a matched cohort study. Clin Microbiol Infect. 2016 Jan;22(1):78.e1-8.  
33.  Karvellas CJ, McPhail M, Pink F, Asthana S, Muiesan P, Heaton N, et al. Bloodstream infection after elective liver 
transplantation is associated with increased mortality in patients with cirrhosis. J Crit Care. 2011 Oct;26(5):468–
74.  
34.  Dalager-Pedersen M, Koch K, Thomsen RW, Schønheyder HC, Nielsen H. The effect of community-acquired 
bacteraemia on return to workforce, risk of sick leave, permanent disability pension and death: a Danish 
population-based cohort study. BMJ Open. 2014 Jan 29 2017 Jul 7];4(1):e004208.  
35.  Nielsen SL, Lassen AT, Gradel KO, Jensen TG, Kolmos HJ, Hallas J, et al. Bacteremia is associated with excess 
long-term mortality: A 12-year population-based cohort study. J Infect. 2015 Feb;70(2):111–26.  
36.  Gotland N, Uhre ML, Mejer N, Skov R, Petersen A, Larsen AR, et al. Long-term mortality and causes of death 
associated with Staphylococcus aureus bacteremia. A matched cohort study. J Infect. 2016 Oct;73(4):346–57.  
37.  Leibovici L, Samra Z, Konigsberger H, Drucker M, Ashkenazi S, Pitlik SD. Long-term survival following bacteremia 
or fungemia. JAMA. 1995 Sep 13;274(10):807–12.  
38.  Wade DT, Collin C. The Barthel ADL Index: a standard measure of physical disability? Int Disabil Stud. 
1988;10(2):64–7.  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
39.  EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990 
Dec;16(3):199–208.  
40.  Dalager-Pedersen M, Søgaard M, Schønheyder HC, Thomsen RW, Baron JA, Nielsen H. Venous thromboembolism 
after community-acquired bacteraemia: a 20-year danish cohort study. Salluh JIF, editor. PLoS One. 2014 Jan 
23;9(1):e86094.  
41.  Levine RL, LeClerc JR, Bailey JE, Monberg MJ, Sarwat S. Venous and arterial thromboembolism in severe sepsis. 
Thromb Haemost. 2008 May 11;99(5):892–8.  
42.  Perl TM, Dvorak L, Hwang T, Wenzel RP. Long-term survival and function after suspected gram-negative sepsis. 
JAMA. 1995 Jul 26;274(4):338–45.  
43.  Rublee D, Opal SM, Schramm W, Keinecke H-O, Knaub S. Quality of life effects of antithrombin III in sepsis 
survivors: results from the KyberSept trial [ISRCTN22931023]. Crit Care. 2002 Aug;6(4):349–56.  
44.  Granja C, Dias C, Costa-Pereira A, Sarmento A. Quality of life of survivors from severe sepsis and septic shock may 
be similar to that of others who survive critical illness. Crit Care. 2004 Apr;8(2):R91.  
45.  Karlsson S, Ruokonen E, Varpula T, Ala-Kokko TI, Pettilä V, Finnsepsis Study Group. Long-term outcome and 
quality-adjusted life years after severe sepsis*. Crit Care Med. 2009 Apr;37(4):1268–74.  
46.  Ou S-M, Chu H, Chao P-W, Lee Y-J, Kuo S-C, Chen T-J, et al. Long-Term Mortality and Major Adverse 
Cardiovascular Events in Sepsis Survivors. A Nationwide Population-based Study. Am J Respir Crit Care Med. 2016 
Jul 15;194(2):209–17.  
47.  Wang T, Derhovanessian A, De Cruz S, Belperio JA, Deng JC, Hoo GS. Subsequent infections in survivors of sepsis: 
epidemiology and outcomes. J Intensive Care Med. 2014 Mar 26;29(2):87–95.  
48.  Alfandari S, Cabaret P, Nguyen S, Descamps D, Vachée A, Cattoen C, et al. Evaluating the management of 493 
patients presenting with bacteremia in 23 northern French hospitals. Médecine Mal Infect. 2016 Jun;46(4):194–9.  
49.  Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: International 
Guidelines for Management of Severe Sepsis and Septic Shock, 2012. Intensive Care Med. 2013 Feb;39(2):165–
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
228.  
 
 
 
Table 1. Study Quality Assessment using the Newcastle Ottawa Scale. 
Study Selection Comparability Outcome 
Tauriainen 2017 **** * *** 
Dalager-Pedersen 2016 **** * ** 
Gotland 2016 **** * *** 
Nielsen 2015 **** * *** 
Dalager-Pedersen 2014a *** * *** 
Dalager-Pedersen 2014b **** * *** 
Mejer 2014 **** * *** 
Karvellas 2011 **** * *** 
Leibovici 1995 **** ** *** 
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Table 2. Characteristics of studies reporting long-term outcomes in patients with bloodstream infection. 
First 
Author/ 
year 
Study design, 
period, 
region 
N/ 
Ratio 
Population 
characteristics 
Case 
matching 
Co- 
Morbid 
state 
Adjustments Duration 
of 
follow 
up 
Outcome 
Tauriainen 
2017 
Retrospective 
comparison 
of BSI and 
non-BSI 
patients post 
coronary 
surgery, 2006 
to 2013, 
Single centre 
in Finland 
27 
(>1:10) 
Adult patients 
undergoing 
isolated 
coronary 
artery bypass 
grafting with a 
BSI identified 
post 
operatively 
Comparison 
to blood 
culture 
negative 
patients and 
all other post 
coronary 
surgery cases 
Yes No adjustments 5 years Mortality at 30 
days, 1 and 5 
years 
Dalager- 
Pedersen 
2016 
Prospective 
case matched 
study in 
adults, 
2011-2014, 
Single site 
800 bed 
community 
hospital, 
North 
Denmark 
71 
(1:1) 
≥18 years 
Hospital 
admission with 
first episode 
community 
acquired 
bloodstream 
infection 
Negative 
blood culture, 
age (18-59, 
60-79, 80+), 
gender, 
duration since 
blood culture 
draw +/- 2 
days 
Yes Age, gender and 
comorbidity 
1 year Functional status 
EQ-5D, Barthel 
Gotland 
2016 
Prospective 
matched 
cohort, 
1992-2014, 
Nationwide 
register in 
Holland 
25,855 
(1:10) 
Registry of 
consecutive 
Staphylococcus 
aureus 
bloodstream 
infection 
Negative 
blood culture, 
Age and 
gender 
Yes Charlson 
Comorbidity index, 
age, gender and 
time period 
5 years Mortality at 1 and 
5 years 
Nielsen 
2015 
Retrospective 
population 
based cohort 
study, 
2000-2008, 
Funen 
County 
Denmark 
7783 
(1:5) 
First time 
bloodstream 
infection 
>14 years of 
age 
Population 
controls 
Absence of 
bloodstream 
infection, 
gender, year 
of birth and 
residency in 
Funen County 
Yes Martial status, 
Charlson 
comorbidity 
classification 
0,1,2,>=3 and a 
history of alcohol 
dependence 
12 years Mortality at 30 
and 90 days, and 1 
year 
Dalager- 
Pedersen 
2014a 
Prospective 
case matched 
study, 1996 
to 2011, 
North 
Denmark 
450 
(1:10) 
Nationwide 
study, 20-58 
years of age 
who were part 
of the 
workforce in 
the 4 weeks 
prior to 
admission. No 
Blood culture 
negative 
controls 
Yes Age (continuous), 
gender and 
presence of 
comorbidity 
(binary). Subgroup 
analysis by 
pre-existing 
disease, COPD, 
recent antibiotic 
1 year Mortality at 30 
days and 1 year 
Return to work, 
utilisation of sick 
leave, disability 
pension.  
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documented 
bloodstream 
infection in the 
previous 
year.1996 to 
2011, 
Northern 
Denmark 
use, LRTI and UTI. 
Dalager- 
Pedersen 
2014b 
Retrospective 
analysis of 
population 
databases 
from 
Northern 
Denmark 
1992-2011. 
4213 
(1:5) 
(1:10) 
Community 
acquired BSI, 
hospital 
admissions ≥15 
years of age, 
1992 to 2011, 
Northern 
Denmark 
Matched 
non-BSI 
hospital 
admission. 
Matched 
population 
controls 
Yes Age, marital 
status, previous 
AMI, previous 
cerebrovascular 
disease, diabetes, 
COPD, other 
cardiovascular 
disease, other 
comorbid disease 
and the use of 
medications for 
cardiovascular 
disease 
1 year Myocardial 
infarction and 
stroke 
Dalager- 
Pedersen 
2014c 
Retrospective 
analysis of 
population 
databases 
from 
Northern 
Denmark 
1992-2011. 
4389 
(1:5) 
(1:10) 
Community 
acquired BSI, 
hospital 
admissions ≥15 
years of age 
Matched 
non-BSI 
hospital 
admission. 
Matched 
population 
controls 
Yes Age, gender, 
cancer, 
cardiovascular 
diseases, diabetes, 
obesity, COPD, 
renal disease and 
recent hospital 
contact 
1 year Mortality at 90 
days and 1 year 
Venous 
thromboembolism 
 
Mejer 
2014 
Nationwide 
register 
based 
retrospective 
matched 
cohort study, 
1995-2008, 
Denmark 
15,669 
(1:10) 
All registered 
cases of SAB 
within the 
Danish 
population >15 
years of age 
during the 
study period 
Absence of 
bloodstream 
infection, age 
and gender 
Yes Previous venous 
thromboembolism, 
intravenous drug 
use, cocaine abuse 
1 year Venous 
thromboembolism 
incidence 
Karvellas 
2011 
Retrospective 
cohort from 
single centre 
in the United 
Kingdom 
15 
(1:13) 
≥17 years post 
liver transplant 
Absence of a 
bloodstream 
infection in a 
post liver 
transplant 
patient 
Yes APACHE II score 5 years Mortality at 1 year 
Leibovici 
1995 
Prospective 
study, 
1988-1992, 
Single centre, 
Israel. 
1991 
(1:1) 
>17 years of 
age 
Age (+/- 5 
years), 
gender, date 
of 
hospitalisation 
(+/- 6 
months), 
department of 
admission, 
comorbidity 
Yes Co-morbid disease 4 years Mortality at 30 
days, 6 months 
and 1 year 
BSI = bloodstream infection, COPD = chronic obstructive lung disease, EQ-5D = EuroQol five dimensions questionnaire  
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Table 3 Proportional difference in mortality with unadjusted risk ratio at reported intervals  
Study 30 day 90 day 180 day 365 day 
Tauriainen 2017     
BSI 11.1 -- -- 18.5 
Non BSI 5.1 -- -- 9.5 
Absolute difference 6 -- -- 9 
Unadjusted relative risk 2.18 (0.72 to 6.62) -- -- 1.94 (0.85 to 4.42) 
     
Gotland 2016     
BSI -- -- -- 44.6 
Non BSI -- -- -- 4.1 
Absolute difference -- -- -- 40.5 
Unadjusted relative risk -- -- -- 10.94 (10.66 to 11.16) 
     
Nielsen 2015     
BSI 22 30.1 -- 41.4 
Non BSI 0.2 0.6 -- 2.6 
Absolute difference 21.8 29.5 -- 38.8 
Unadjusted relative risk 114.2(90.82 to 143.7) 50.66(44.36 to 57.86) -- 16.19(15.14 to 17.31) 
     
Dalager-Pedersen 2014a     
BSI 4.0 -- -- 8.0 
Non BSI 1.4 -- -- 3.9 
Absolute difference 3.6 -- -- 4.1 
Unadjusted relative risk 2.80(1.71 to 4.59) -- -- 2.05(1.47 to 2.86) 
     
Dalager-Pedersen 2014c     
BSI -- 20.5 -- 29.3 
Non BSI -- 12.5 -- 21.6 
Absolute difference -- 8.0 -- 7.7 
Unadjusted relative risk -- 1.64 (1.53 to 1.76) -- 1.36 (1.29 to 1.43) 
     
Karvellas 2011     
BSI -- -- -- 60 
Non BSI -- -- -- 6 
Absolute difference -- -- -- 54 
Unadjusted relative risk -- -- -- 9.97(5.10 to 19.48) 
     
Leibovici 1995     
BSI 26 -- 43 48 
Non BSI 7 -- 19 27 
Absolute difference 19 -- 24 21 
Unadjusted relative risk 3.73(3.12 to 4.45) -- 2.26(2.04 to 2.51) 1.78(1.6 to 1.94) 
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Table 4. Studies assessing morbidity at 1 year for BSI and non-BSI matched cohort, and risk assessment. 
Study Morbidity measure 
% Morbidity at 1 year bloodstream 
infection cohort 
% Morbidity at 1 year 
matched cohort 
Adjusted risk of 
morbidity 
Dalager-Pedersen 
2016 
Risk for deterioration in 
Barthel-20 11 7 1.6 (0.5-4.5) 
 
Risk for deterioration in 
EQ-5D-3L 38 31 1.3 (0.8-2.1) 
Dalager-Pedersen 
2014a Sick leave 40.2 23.9 1.51(1.34-1.70) 
 
Disability pension 2.7 2.6 0.99 (0.48-2.02) 
Dalager-Pedersen 
2014b Myocardial infarct 0.5 0.6 0.91(0.52-1.60) 
 
Stroke 0.6 0.7 0.71(0.42-1.20) 
Dalager-Pedersen 
2014c 
Venous 
thromboembolism 0.5 0.3 1.4(0.8-2.5) 
Mejer 2014 Deep vein thrombosis 9.5(7.0–12.9) 2.0(1.8–2.2) 
 
 
Pulmonary embolism 3.0(1.7–5.1) 1.6(1.4–1.8) 
 
 
Risk of venous thromboembolism after exclusion of prior VTE, IVDU or cocaine use 4.5(3.2–6.2) 
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Figure 3 
 
